MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2019 International Congress

    Increasing chances of detecting a neuroprotective signal in PhI/II PD clinical trials?

    S. Palfi, C. Denot, A. Bousseau, JC. Corvol (Paris, France)

    Objective: Design an early CT program to detect a neuroprotective signal in PD. Background: Attempts to develop PD modifying therapies have been largely disappointing so…
  • 2019 International Congress

    Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study

    S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, W. Meissner, F. Tison, O. Rascol (Bordeaux, France)

    Objective: To explore amantadine IR utilization patterns in the French COPARK study. Background: Immediate release (IR) amantadine is marketed for the treatment of early and…
  • 2019 International Congress

    Yerba mate tea (Ilex paraguariensis) exerts a neuroprotective effect on intrastriatal 6-OHDA-lesioned mice model of Parkinson’s disease

    I. Taravini, G. Gomez, L. Tribbia, A. Cura, R. Rivero, M. Bernardi, J. Ferrario, B. Baldi-Coronel, O. Gershanik, E. Gatto (Gualeguaychú, Argentina)

    Objective: We set to investigate the possible neuroprotective effect of yerba mate (YM) consumption on dopaminergic neurons in a mice model of Parkinson’s disease (PD). Background: The motor…
  • 2019 International Congress

    Ferroptosis, a recently identified cell death, as a therapeutic target for Parkinson’s disease.

    H. Bouchaoui, L. Mahoney-Sanchez, A. Jonneaux, F. Gouel, M. Dutheil, JC. Devedjian, G. Garçon, D. Devos (Lille, France)

    Objective: We aim to determine in a cell model neuroprotective effects of targeting lipoxygenases (LOXs), central players in Ferroptosis, a novel regulated iron-dependent cell death…
  • 2019 International Congress

    Development of Mucoadhesive Sustained Release Floating Tablets of Silymarin using Natural Polymer for Improved Anti-Parkinson Efficacy

    D. Gugulothu, R. Nagapuri, DK. Khatri (Pune, India)

    Objective: The objective of the present investigation was to develop Mucoadhesive sustained release floating tablets of Silymarin using natural polymers (Coccinia grandis and Rumex vasicarious)…
  • 2019 International Congress

    Alleviation of Parkinson’s and Associated Depression using Silymarin in Rotenone induced Mice Model of Parkinson’s Disease

    D. Khatri (Pune, India)

    Objective: The present study was undertaken in order find out the possible neuroprotective and antidepressant potential of Silymarin. The neuroprotective and antidepressant potential was evaluated…
  • 2019 International Congress

    Pre-diagnosis physical activity habits are associated with age of diagnosis and postural instability in Parkinson’s disease

    M. Landers, K. Johnson, S. Johnson, J. Lyle, T. Ormsby, D. Salgo, J. Zorn, A. Murtishaw, A. Salazar, J. Kinney (Las Vegas, NV, USA)

    Objective: To determine if pre-diagnosis exercise and brain-derived neurotrophic factor (BDNF) genotype are predictive of age at diagnosis and severity of balance impairment. Background: Studies…
  • 2019 International Congress

    Park-Ease Trial: A Randomized Controlled Trial to Study the Efficacy of Exercises in Early-Stage Parkinson’s Disease

    R. Swarnakar, S. Wadhwa, S. V, V. Goyal, V. Sreenivas (New Delhi, India)

    Objective: To evaluate the efficacy of exercises in early-stage Parkinson’s Disease by observing improvement in motor symptoms assessed by Unified Parkinson’s Disease Rating Scale (UPDRS)…
  • 2019 International Congress

    Investigation into the causes of reduced caffeine levels in Parkinson’s disease

    MI. de Bartolo, G. Leodori, A. Fabbrini, M. Costanzo, D. Belvisi, A. Conte, S. Manetto, A. Ciogli, C. Villani, A. Berardelli, G. Fabbrini (Rome, Italy)

    Objective: To find out whether PD patients show decreased salivary caffeine levels; to investigate CYP1A2-phenotype and caffeine absorption as possible causes of decreased caffeine levels…
  • 2019 International Congress

    Limitations of Curcumin as a Therapeutic Agent in Rotenone Induced Dopaminergic Neurodegeneration: Insights from Drosophila Model of Parkinson’s Disease

    M. Ayajuddin, SC. Yenisetti (Zunheboto, India)

    Objective: To understand the efficacy of curcumin in rotenone induced Drosophila model of Parkinson’s disease. Background: Parkinson’s disease (PD) is the second most common neurodegenerative…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley